Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list

This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority Pathogens List. PubMed and Web of Science were used to find studies reporting m...

Descripción completa

Detalles Bibliográficos
Autores: McMullan, Brendan, Kim, Hannah Yejin, Alastruey-Izquierdo, Ana, Tacconelli, Evelina, Dao, Aiken, Oladele, Rita, Tanti, Daniel, Govender, Nelesh P, Shin, Jong-Hee, Heim, Jutta, Ford, Nathan Paul, Huttner, Benedikt, Galas, Marcelo, Nahrgang, Saskia Andrea, Gigante, Valeria, Sati, Hatim, Alffenaar, Jan Willem, Morrissey, C Orla, Beardsley, Justin
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/26448
Acceso en línea:https://hdl.handle.net/20.500.12105/26448
Access Level:acceso abierto
Palabra clave:Pneumocystis jirovecii
PCP
Immunosuppression
Invasive fungal infection
Pneumonia
Antifungal Agents
Global Health
Humans
Immunocompromised Host
Incidence
Invasive Fungal Infections
Pneumocystis carinii
Pneumonia, Pneumocystis
Risk Factors
World Health Organization
Descripción
Sumario:This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority Pathogens List. PubMed and Web of Science were used to find studies reporting mortality, inpatient care, complications/sequelae, antifungal susceptibility/resistance, preventability, annual incidence, global distribution, and emergence in the past 10 years, published from January 2011 to February 2021. Reported mortality is highly variable, depending on the patient population: In studies of persons with HIV, mortality was reported at 5%-30%, while in studies of persons without HIV, mortality ranged from 4% to 76%. Risk factors for disease principally include immunosuppression from HIV, but other types of immunosuppression are increasingly recognised, including solid organ and haematopoietic stem cell transplantation, autoimmune and inflammatory disease, and chemotherapy for cancer. Although prophylaxis is available and generally effective, burdensome side effects may lead to discontinuation. After a period of decline associated with improvement in access to HIV treatment, new risk groups of immunosuppressed patients with PJP are increasingly identified, including solid organ transplant patients.

Similares en LA Referencia